Floatz logo

NOGITECAN

Neuroendocrine Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Neuroendocrine Carcinoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2B
Everolimus
AIO-Studien-gGmbH
Phase 2B
Lurbinectedin
Jazz Pharmaceuticals
Phase 2B
Pembrolizumab
Ochsner Health System
Phase 2B
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 2B

View all 50 →

Same molecule, other indications

NOGITECAN is also rated in:

primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative · Phase 2
72 / 100
View asset →
non-small cell lung carcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →